Abstract

Introduction. Trypanosoma theileri (T.theileri) is apathogenic, cosmopolitan and commensal protozoa of cattle. Despite apathogenic in healthy, but not in stressed cattle; it’s getting recent attention as a tool to tackle pathogenic ones. These days, researchers are giving due attention to study the biology and feasibility of T.theilerito use it as a model candidate for novel drug discovery. In addition, in-silico analysis using common antitrypanosome drug targets couldn’t show significant similarity both at DNA and protein level. Nevertheless, homologous sequences have been identified among drug targets for Ornithine decarboxylase. This indicated the possibility to consider T.theileri as a model to search novel drugs once having whole genome sequences. The SDM 79 is an appropriate medium to cultivate at 26 oC, without CO2. Gradient PCR amplification has been used to detect using T. theileri. The specific primer (Tth625) which reveals 465 bp amplification product and also the full length 18S ribosomal DNA sequence of T.theileri DNA detectable at 730 base pairs are commonly used. Whole genome and transcriptome analysis can show the phylogenetic relationship between T.theileri and other pathogenic Trypanosomes which can be the basis for novel drugs development. Aim. The purpose of this paper is toreview the nature of Trypanosoma theileri, its molecular identification and also using its apathogenic nature as an opportunity to discover anew Trypanocidal drug.